-
1
-
-
52949107622
-
Treatment of hyperlipidaemia with fenofibrate and related fibrates
-
Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17:1599-614.
-
(2008)
Expert Opin Investig Drugs.
, vol.17
, pp. 1599-1614
-
-
Filippatos, T.1
Milionis, H.J.2
-
2
-
-
79960441327
-
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
-
Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945-58.
-
(2011)
Expert Opin Pharmacother.
, vol.12
, pp. 1945-1958
-
-
Filippatos, T.D.1
Elisaf, M.S.2
-
3
-
-
78649874149
-
Combination of fenofibrate with non-statin drug regimens
-
Agouridis AP, Filippatos TD, Derdemezis CS, Mikhailidis DP, Elisaf MS. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010;16:3401-16.
-
(2010)
Curr Pharm Des.
, vol.16
, pp. 3401-3416
-
-
Agouridis, A.P.1
Filippatos, T.D.2
Derdemezis, C.S.3
Mikhailidis, D.P.4
Elisaf, M.S.5
-
4
-
-
39149145837
-
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
-
Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 2008;155:499e9-16.
-
(2008)
Am Heart J.
, vol.155
-
-
Rosenson, R.S.1
-
5
-
-
53449092689
-
Atorvastatin and fenofibrate have comparable effects on VLDLapolipoprotein C-III kinetics in men with the metabolic syndrome
-
Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH. Atorvastatin and fenofibrate have comparable effects on VLDLapolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1831-7.
-
(2008)
Arterioscler Thromb Vasc Biol.
, vol.28
, pp. 1831-1837
-
-
Chan, D.C.1
Watts, G.F.2
Ooi, E.M.3
Ji, J.4
Johnson, A.G.5
Barrett, P.H.6
-
6
-
-
77954078831
-
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
-
Hamilton SJ, Chew GT, Davis TM, Watts GF. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients. Clin Sci (Lond). 2010;118:607-15.
-
(2010)
Clin Sci (Lond).
, vol.118
, pp. 607-615
-
-
Hamilton, S.J.1
Chew, G.T.2
Davis, T.M.3
Watts, G.F.4
-
7
-
-
0033986077
-
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state
-
DOI 10.1097/00005344-200001000-00022
-
Genest Jr J, Nguyen NH, Theroux P, Davignon J, Cohn JS. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol. 2000;35:164-72. (Pubitemid 30032909)
-
(2000)
Journal of Cardiovascular Pharmacology
, vol.35
, Issue.1
, pp. 164-172
-
-
Genest Jr., J.1
Nguyen, N.-H.2
Theroux, P.3
Davignon, J.4
Cohn, J.S.5
-
8
-
-
48549104782
-
Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
-
Filippatos T, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis D, et al. Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. J Clin Lipidol. 2008;2:279-84.
-
(2008)
J Clin Lipidol.
, vol.2
, pp. 279-284
-
-
Filippatos, T.1
Tsimihodimos, V.2
Kostapanos, M.3
Kostara, C.4
Bairaktari, E.5
Kiortsis, D.6
-
9
-
-
60849116123
-
Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
-
Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 2009;17:504-9.
-
(2009)
Obesity (Silver Spring).
, vol.17
, pp. 504-509
-
-
Rosenson, R.S.1
-
10
-
-
76149092815
-
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
-
Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010;95:829-36.
-
(2010)
J Clin Endocrinol Metab.
, vol.95
, pp. 829-836
-
-
Belfort, R.1
Berria, R.2
Cornell, J.3
Cusi, K.4
-
11
-
-
0023634450
-
Pharmacology of fenofibrate
-
Chapman MJ. Pharmacology of fenofibrate.AmJMed. 1987;83:21-5.
-
(1987)
Am J Med.
, vol.83
, pp. 21-25
-
-
Chapman, M.J.1
-
12
-
-
79151484278
-
Management of dyslipidemias with fibrates, alone and in combination with statins: Role of delayed-release fenofibric acid
-
Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: Role of delayed-release fenofibric acid. Vasc Health Risk Manag. 2010;6:525-39.
-
(2010)
Vasc Health Risk Manag.
, vol.6
, pp. 525-539
-
-
Moutzouri, E.1
Kei, A.2
Elisaf, M.S.3
Milionis, H.J.4
-
13
-
-
84864484860
-
-
Trilipix [Package insert]. North Chicago IL: Abbott Laboratories; 2009. Available from: Accessed on May 26
-
Trilipix [Package insert]. North Chicago, IL: Abbott Laboratories; 2009. Available from: Http://www.trilipixpro.com/. Accessed on May 26, 2010.
-
(2010)
-
-
-
14
-
-
77955909914
-
Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
-
Alagona Jr P. Fenofibric acid: A new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag. 2010;6:351-62.
-
(2010)
Vasc Health Risk Manag.
, vol.6
, pp. 351-362
-
-
Alagona Jr., P.1
-
15
-
-
17644426320
-
Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes
-
DOI 10.1007/s11095-004-9011-5
-
Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res. 2005;22:71-8. (Pubitemid 40558148)
-
(2005)
Pharmaceutical Research
, vol.22
, Issue.1
, pp. 71-78
-
-
Prueksaritanont, T.1
Richards, K.M.2
Qiu, Y.3
Strong-Basalyga, K.4
Miller, A.5
Li, C.6
Eisenhandler, R.7
Carlini, E.J.8
-
16
-
-
74549205313
-
Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk
-
Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med. 2010;123:151-7.
-
(2010)
Am J Med.
, vol.123
, pp. 151-157
-
-
Schelleman, H.1
Bilker, W.B.2
Brensinger, C.M.3
Wan, F.4
Yang, Y.X.5
Hennessy, S.6
-
18
-
-
0037292311
-
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
-
DOI 10.1016/S0149-2918(03)80089-9
-
Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25:459-71. (Pubitemid 36286913)
-
(2003)
Clinical Therapeutics
, vol.25
, Issue.2
, pp. 459-471
-
-
Martin, P.D.1
Dane, A.L.2
Schneck, D.W.3
Warwick, M.J.4
-
19
-
-
58149181570
-
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans
-
Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009;49:63-71.
-
(2009)
J Clin Pharmacol.
, vol.49
, pp. 63-71
-
-
Zhu, T.1
Awni, W.M.2
Hosmane, B.3
Kelly, M.T.4
Sleep, D.J.5
Stolzenbach, J.C.6
-
20
-
-
30344436628
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions
-
DOI 10.1517/14740338.5.1.145
-
Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006;5:145-56. (Pubitemid 43056446)
-
(2006)
Expert Opinion on Drug Safety
, vol.5
, Issue.1
, pp. 145-156
-
-
Davidson, M.H.1
-
21
-
-
51549122051
-
Evaluation of a new formulation of fenofibric acid, ABT- 335, co-administered with statins: Study design and rationale of a phase III clinical programme
-
Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, et al. Evaluation of a new formulation of fenofibric acid, ABT- 335, co-administered with statins: Study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28:625-34.
-
(2008)
Clin Drug Investig.
, vol.28
, pp. 625-634
-
-
Jones, P.H.1
Bays, H.E.2
Davidson, M.H.3
Kelly, M.T.4
Buttler, S.M.5
Setze, C.M.6
-
22
-
-
57149105884
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study
-
Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Am Heart J. 2009;157:195-203.
-
(2009)
Am Heart J.
, vol.157
, pp. 195-203
-
-
Mohiuddin, S.M.1
Pepine, C.J.2
Kelly, M.T.3
Buttler, S.M.4
Setze, C.M.5
Sleep, D.J.6
-
23
-
-
59049086841
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia
-
Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103:515-22.
-
(2009)
Am J Cardiol.
, vol.103
, pp. 515-522
-
-
Goldberg, A.C.1
Bays, H.E.2
Ballantyne, C.M.3
Kelly, M.T.4
Buttler, S.M.5
Setze, C.M.6
-
24
-
-
67349119255
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study
-
Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis. 2009;204:208-15.
-
(2009)
Atherosclerosis.
, vol.204
, pp. 208-215
-
-
Jones, P.H.1
Davidson, M.H.2
Kashyap, M.L.3
Kelly, M.T.4
Buttler, S.M.5
Setze, C.M.6
-
25
-
-
57349155535
-
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia
-
DOI 10.1016/j.jacl.2008.10.001, PII S1933287408008878
-
Bays H, Jones P, Mohiuddin S, Kelly M, Sun H, Setze C, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426-35. (Pubitemid 352795715)
-
(2008)
Journal of Clinical Lipidology
, vol.2
, Issue.6
, pp. 426-435
-
-
Bays, H.E.1
Jones, P.H.2
Mohiuddin, S.M.3
Kelly, M.T.4
Sun, H.5
Setze, C.M.6
Buttler, S.M.7
Sleep, D.J.8
Stolzenbach, J.C.9
-
26
-
-
72049124300
-
Year two assessment of fenofibric acid and moderate-dose statin combination: A phase 3, open-label, extension study
-
Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, et al. Year two assessment of fenofibric acid and moderate-dose statin combination: A phase 3, open-label, extension study. Clin Drug Investig. 2010;30:51-61.
-
(2010)
Clin Drug Investig.
, vol.30
, pp. 51-61
-
-
Kipnes, M.S.1
Roth, E.M.2
Rhyne, J.M.3
Setze, C.M.4
Lele, A.5
Kelly, M.T.6
-
27
-
-
77950127995
-
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: Results of a pooled subgroup analysis from three randomized, controlled, double-blind trials
-
Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: Results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010;10:73-84.
-
(2010)
Am J Cardiovasc Drugs.
, vol.10
, pp. 73-84
-
-
Jones, P.H.1
Cusi, K.2
Davidson, M.H.3
Kelly, M.T.4
Setze, C.M.5
Thakker, K.6
-
28
-
-
77953264127
-
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatinmonotherapy in patients with hypercholesterolemia and hypertriglyceridemia: A randomized, double-blind study
-
Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatinmonotherapy in patients with hypercholesterolemia and hypertriglyceridemia: A randomized, double-blind study. Am J Cardiovasc Drugs. 2010;10:175-86.
-
(2010)
Am J Cardiovasc Drugs.
, vol.10
, pp. 175-186
-
-
Roth, E.M.1
McKenney, J.M.2
Kelly, M.T.3
Setze, C.M.4
Carlson, D.M.5
Gold, A.6
-
29
-
-
79958200219
-
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-A phase 3 study
-
Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421-8.
-
(2010)
Cardiovasc Drugs Ther.
, vol.24
, pp. 421-428
-
-
Roth, E.M.1
Rosenson, R.S.2
Carlson, D.M.3
Fukumoto, S.M.4
Setze, C.M.5
Blasetto, J.W.6
-
30
-
-
77957857200
-
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
-
Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010;160:759-66.
-
(2010)
Am Heart J.
, vol.160
, pp. 759-766
-
-
Jones, P.H.1
Goldberg, A.C.2
Knapp, H.R.3
Kelly, M.T.4
Setze, C.M.5
Stolzenbach, J.C.6
-
31
-
-
79551640176
-
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia
-
Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, et al. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care. 2010;33:2113-6.
-
(2010)
Diabetes Care.
, vol.33
, pp. 2113-2116
-
-
Bays, H.E.1
Roth, E.M.2
McKenney, J.M.3
Kelly, M.T.4
Thakker, K.M.5
Setze, C.M.6
-
32
-
-
27444443876
-
Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement
-
DOI 10.1161/CIRCULATIONAHA.105.169404
-
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52. (Pubitemid 41532612)
-
(2005)
Circulation
, vol.112
, Issue.17
, pp. 2735-2752
-
-
Grundy, S.M.1
Cleeman, J.I.2
Daniels, S.R.3
Donato, K.A.4
Eckel, R.H.5
Franklin, B.A.6
Gordon, D.J.7
Krauss, R.M.8
Savage, P.J.9
Smith Jr., S.C.10
Spertus, J.A.11
Costa, F.12
-
33
-
-
77549087054
-
Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials
-
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials. Lancet. 2010;375:735-42.
-
(2010)
Lancet.
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
Welsh, P.4
Buckley, B.M.5
De Craen, A.J.6
-
34
-
-
78349263826
-
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: Subanalysis of two randomized, controlled studies
-
Pepine CJ, Jacobson TA, CarlsonDM, Kelly MT, SetzeCM, Gold A, et al. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: Subanalysis of two randomized, controlled studies. Clin Cardiol. 2010;33:609-19.
-
(2010)
Clin Cardiol.
, vol.33
, pp. 609-619
-
-
Pepine, C.J.1
Jacobson, T.A.2
Carlson, D.M.3
Kelly, M.T.4
Setze, C.M.5
Gold, A.6
-
35
-
-
42049086344
-
Fibrate-associated adverse effects beyond muscle and liver toxicity
-
DOI 10.2174/138161208783885362
-
Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrateassociated adverse effects beyond muscle and liver toxicity. Curr Pharm Des. 2008;14:574-87. (Pubitemid 351516880)
-
(2008)
Current Pharmaceutical Design
, vol.14
, Issue.6
, pp. 574-587
-
-
Florentin, M.1
Liberopoulos, E.N.2
Mikhailidis, D.P.3
Elisaf, M.S.4
-
36
-
-
35248885161
-
Statin-associated adverse effects beyond muscle and liver toxicity
-
DOI 10.1016/j.atherosclerosis.2006.10.001, PII S0021915006006034
-
Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195:7-16. (Pubitemid 47561937)
-
(2007)
Atherosclerosis
, vol.195
, Issue.1
, pp. 7-16
-
-
Kiortsis, D.N.1
Filippatos, T.D.2
Mikhailidis, D.P.3
Elisaf, M.S.4
Liberopoulos, E.N.5
-
37
-
-
1542314891
-
Current overview of statin-induced myopathy
-
DOI 10.1016/j.amjmed.2003.10.033, PII S0002934303007757
-
Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408-16. (Pubitemid 38299486)
-
(2004)
American Journal of Medicine
, vol.116
, Issue.6
, pp. 408-416
-
-
Rosenson, R.S.1
-
39
-
-
0037083071
-
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
-
DOI 10.1016/S0002-9149(01)02258-5, PII S0002914901022585
-
Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89:390-4. (Pubitemid 34142511)
-
(2002)
American Journal of Cardiology
, vol.89
, Issue.4
, pp. 390-394
-
-
Taher, T.H.1
Dzavik, V.2
Reteff, E.M.3
Pearson, G.J.4
Woloschuk, B.L.5
Francis, G.A.6
-
41
-
-
11144239674
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
-
DOI 10.1016/j.amjcard.2004.08.076, PII S0002914904014602
-
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-2. (Pubitemid 40051126)
-
(2005)
American Journal of Cardiology
, vol.95
, Issue.1
, pp. 120-122
-
-
Jones, P.H.1
Davidson, M.H.2
-
42
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366:1849-61.
-
(2005)
Lancet.
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
Best, J.4
Scott, R.5
Taskinen, M.R.6
-
43
-
-
29144456017
-
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study
-
DOI 10.1185/030079905X75078, 3219
-
Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study. Curr Med Res Opin. 2005;21:1997-2006. (Pubitemid 41803111)
-
(2005)
Current Medical Research and Opinion
, vol.21
, Issue.12
, pp. 1997-2006
-
-
Filippatos, T.D.1
Kiortsis, D.N.2
Liberopoulos, E.N.3
Georgoula, M.4
Mikhailidis, D.P.5
Elisaf, M.S.6
-
47
-
-
2342487350
-
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels
-
DOI 10.1517/14740338.3.2.101
-
Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf. 2004;3:101-11. (Pubitemid 38765193)
-
(2004)
Expert Opinion on Drug Safety
, vol.3
, Issue.2
, pp. 101-111
-
-
Dierkes, J.1
Westphal, S.2
Luley, C.3
-
48
-
-
1442301511
-
Fenofibrate Increases Homocystinemia through a PPARα-Mediated Mechanism
-
DOI 10.1097/00005344-200403000-00017
-
Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol. 2004;43:452-3. (Pubitemid 38270613)
-
(2004)
Journal of Cardiovascular Pharmacology
, vol.43
, Issue.3
, pp. 452-453
-
-
Luc, G.1
Jacob, N.2
Bouly, M.3
Fruchart, J.-C.4
Staels, B.5
Giral, P.6
-
49
-
-
0037126526
-
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
-
(2002)
Circulation.
, vol.106
, pp. 3143-3421
-
-
-
50
-
-
4544275379
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
-
Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-32.
-
(2004)
J Am Coll Cardiol.
, vol.44
, pp. 720-732
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
Brewer Jr., H.B.4
Clark, L.T.5
Hunninghake, D.B.6
-
51
-
-
26244432388
-
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
-
(2005)
Lancet.
, vol.366
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
Blackwell, L.4
Buck, G.5
Pollicino, C.6
-
52
-
-
78751680407
-
Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170 255 patients from 76 randomized trials
-
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170 255 patients from 76 randomized trials. QJM. 2011;104:109-24.
-
(2011)
QJM.
, vol.104
, pp. 109-124
-
-
Mills, E.J.1
Wu, P.2
Chong, G.3
Ghement, I.4
Singh, S.5
Akl, E.A.6
-
53
-
-
74549195050
-
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): Overall findings from eight countries
-
Hermans MP, Castro Cabezas M, Strandberg T, Ferrieres J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): Overall findings from eight countries. Curr Med Res Opin. 2010;26:445-54.
-
(2010)
Curr Med Res Opin.
, vol.26
, pp. 445-454
-
-
Hermans, M.P.1
Castro Cabezas, M.2
Strandberg, T.3
Ferrieres, J.4
Feely, J.5
Elisaf, M.6
-
54
-
-
77954051563
-
Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-The CEPHEUS-Greece survey
-
Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Angiology. 2010;61:465-74.
-
(2010)
Angiology.
, vol.61
, pp. 465-474
-
-
Elisaf, M.S.1
Nikas, N.2
-
55
-
-
79952427007
-
Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS
-
da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol. 2011;30:47-63.
-
(2011)
Rev Port Cardiol.
, vol.30
, pp. 47-63
-
-
Da Silva, P.M.1
Cardoso, S.M.2
-
56
-
-
56349154187
-
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
-
Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102:1K-34K.
-
(2008)
Am J Cardiol.
, vol.102
-
-
Fruchart, J.C.1
Sacks, F.2
Hermans, M.P.3
Assmann, G.4
Brown, W.V.5
Ceska, R.6
-
57
-
-
78449267756
-
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial
-
Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet. 2010;376:1658-69.
-
(2010)
Lancet.
, vol.376
, pp. 1658-1669
-
-
Armitage, J.1
Bowman, L.2
Wallendszus, K.3
Bulbulia, R.4
Rahimi, K.5
Haynes, R.6
-
58
-
-
35748972380
-
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol
-
DOI 10.1016/j.amjcard.2007.06.058, PII S0002914907014993
-
Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499-501. (Pubitemid 350050854)
-
(2007)
American Journal of Cardiology
, vol.100
, Issue.10
, pp. 1499-1501
-
-
Alsheikh-Ali, A.A.1
Lin, J.-L.2
Abourjaily, P.3
Ahearn, D.4
Kuvin, J.T.5
Karas, R.H.6
-
59
-
-
33846637379
-
Triglycerides and the risk of coronary heart disease: 10 158 Incident cases among 262 525 participants in 29 Western prospective studies
-
DOI 10.1161/CIRCULATIONAHA.106.637793, PII 0000301720070130000007
-
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-8. (Pubitemid 46184196)
-
(2007)
Circulation
, vol.115
, Issue.4
, pp. 450-458
-
-
Sarwar, N.1
Danesh, J.2
Eiriksdottir, G.3
Sigurdsson, G.4
Wareham, N.5
Bingham, S.6
Boekholdt, S.M.7
Khaw, K.-T.8
Gudnason, V.9
-
60
-
-
64749100269
-
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma
-
Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327-38.
-
(2009)
Biochim Biophys Acta.
, vol.1791
, pp. 327-338
-
-
Tellis, C.C.1
Tselepis, A.D.2
-
61
-
-
33846192751
-
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
-
DOI 10.1517/14712598.7.1.53
-
Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53-72. (Pubitemid 46091576)
-
(2007)
Expert Opinion on Biological Therapy
, vol.7
, Issue.1
, pp. 53-72
-
-
Gazi, I.F.1
Tsimihodimos, V.2
Tselepis, A.D.3
Elisaf, M.4
Mikhailidis, D.P.5
-
62
-
-
59749092544
-
Creactive protein and coronary heart disease: Predictive test or therapeutic target?
-
Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ. Creactive protein and coronary heart disease: Predictive test or therapeutic target? Clin Chem. 2009;55:239-55.
-
(2009)
Clin Chem.
, vol.55
, pp. 239-255
-
-
Hingorani, A.D.1
Shah, T.2
Casas, J.P.3
Humphries, S.E.4
Talmud, P.J.5
-
63
-
-
57849130447
-
Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects withmetabolic syndrome
-
Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari E, Kiortsis DN, et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects withmetabolic syndrome. Arch Med Sci. 2008;4:263-9.
-
(2008)
Arch Med Sci.
, vol.4
, pp. 263-269
-
-
Filippatos, T.D.1
Tsimihodimos, V.2
Kostapanos, M.3
Kostara, C.4
Bairaktari, E.5
Kiortsis, D.N.6
-
65
-
-
34548062085
-
Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients
-
DOI 10.1007/BF02848780
-
Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients. Adv Ther. 2007;24:575-82. (Pubitemid 47295434)
-
(2007)
Advances in Therapy
, vol.24
, Issue.3
, pp. 575-582
-
-
Rizzo, M.1
Rini, G.B.2
Berneis, K.3
-
66
-
-
35148866515
-
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2
-
DOI 10.1161/ATVBAHA.107.147280
-
Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27:2236-43. (Pubitemid 350287255)
-
(2007)
Arteriosclerosis, Thrombosis, and Vascular Biology
, vol.27
, Issue.10
, pp. 2236-2243
-
-
Saougos, V.G.1
Tambaki, A.P.2
Kalogirou, M.3
Kostapanos, M.4
Gazi, I.F.5
Wolfert, R.L.6
Elisaf, M.7
Tselepis, A.D.8
-
67
-
-
38749099455
-
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels
-
DOI 10.1016/j.amjcard.2007.08.035, PII S0002914907019091
-
Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008;101:315-8. (Pubitemid 351175627)
-
(2008)
American Journal of Cardiology
, vol.101
, Issue.3
, pp. 315-318
-
-
Ai, M.1
Otokozawa, S.2
Asztalos, B.F.3
Nakajima, K.4
Stein, E.5
Jones, P.H.6
Schaefer, E.J.7
-
68
-
-
77953231187
-
The effects of ezetimibe and/or orlistat on triglyceriderich lipoprotein metabolism in obese hypercholesterolemic patients
-
Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceriderich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010;45:445-50.
-
(2010)
Lipids.
, vol.45
, pp. 445-450
-
-
Nakou, E.S.1
Filippatos, T.D.2
Agouridis, A.P.3
Kostara, C.4
Bairaktari, E.T.5
Elisaf, M.S.6
-
69
-
-
47949099324
-
Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp- PLA2) activity in healthy obese women
-
Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp- PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis. 2008;18:477-82.
-
(2008)
Nutr Metab Cardiovasc Dis.
, vol.18
, pp. 477-482
-
-
Tzotzas, T.1
Filippatos, T.D.2
Triantos, A.3
Bruckert, E.4
Tselepis, A.D.5
Kiortsis, D.N.6
-
70
-
-
47949116865
-
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia
-
Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919-29.
-
(2008)
Curr Med Res Opin.
, vol.24
, pp. 1919-1929
-
-
Nakou, E.S.1
Filippatos, T.D.2
Georgoula, M.3
Kiortsis, D.N.4
Tselepis, A.D.5
Mikhailidis, D.P.6
-
71
-
-
34249005579
-
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia
-
DOI 10.1185/030079907X188062
-
Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, Tselepis AD, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23:1169-76. (Pubitemid 46799601)
-
(2007)
Current Medical Research and Opinion
, vol.23
, Issue.5
, pp. 1169-1176
-
-
Kalogirou, M.1
Tsimihodimos, V.2
Gazi, I.3
Filippatos, T.4
Saougos, V.5
Tselepis, A.D.6
Mikhailidis, D.P.7
Elisaf, M.8
-
72
-
-
34548297933
-
A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia
-
DOI 10.1016/j.clinthera.2007.07.019, PII S0149291807002111
-
Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007;29:1403-14. (Pubitemid 47348117)
-
(2007)
Clinical Therapeutics
, vol.29
, Issue.7
, pp. 1403-1414
-
-
Kostapanos, M.S.1
Milionis, H.J.2
Filippatos, T.D.3
Nakou, E.S.4
Bairaktari, E.T.5
Tselepis, A.D.6
Elisaf, M.S.7
-
73
-
-
77956745760
-
Effect of non-statin lipid lowering and antiobesity drugs on LDL subfractions in patients with mixed dyslipidaemia
-
Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and antiobesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010;8:820-30.
-
(2010)
Curr Vasc Pharmacol.
, vol.8
, pp. 820-830
-
-
Florentin, M.1
Tselepis, A.D.2
Elisaf, M.S.3
Rizos, C.V.4
Mikhailidis, D.P.5
Liberopoulos, E.N.6
-
75
-
-
79954523255
-
Combination drug treatment in patients with non-alcoholic fatty liver disease
-
Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol. 2010;2:139-42.
-
(2010)
World J Hepatol.
, vol.2
, pp. 139-142
-
-
Filippatos, T.D.1
Elisaf, M.S.2
-
76
-
-
67249098263
-
Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors
-
Filippatos T, Derdemezis C, Elisaf M. Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clin Lipidol. 2009;4:331-41.
-
(2009)
Clin Lipidol.
, vol.4
, pp. 331-341
-
-
Filippatos, T.1
Derdemezis, C.2
Elisaf, M.3
-
77
-
-
64749115172
-
Lipid-lowering drugs acting at the level of the gastrointestinal tract
-
Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des. 2009;15:490-516.
-
(2009)
Curr Pharm Des.
, vol.15
, pp. 490-516
-
-
Filippatos, T.D.1
Mikhailidis, D.P.2
-
78
-
-
65549092827
-
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: Different effects on LDL-profiles
-
Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: Different effects on LDL-profiles. Eur J Clin Invest. 2009;39:463-70.
-
(2009)
Eur J Clin Invest.
, vol.39
, pp. 463-470
-
-
Winkler, K.1
Schewe, T.2
Putz, G.3
Odunc, N.4
Schafer, G.5
Siegel, E.6
-
79
-
-
38849179382
-
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study
-
May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study). Am J Cardiol. 2008;101:486-9.
-
(2008)
Am J Cardiol.
, vol.101
, pp. 486-499
-
-
May, H.T.1
Anderson, J.L.2
Pearson, R.R.3
Jensen, J.R.4
Horne, B.D.5
Lavasani, F.6
-
80
-
-
43849104295
-
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
-
DOI 10.1016/j.metabol.2008.01.026, PII S0026049508000553
-
Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients withmixed hyperlipidemia. Metabolism. 2008;57:796-801. (Pubitemid 351697911)
-
(2008)
Metabolism: Clinical and Experimental
, vol.57
, Issue.6
, pp. 796-801
-
-
Tribble, D.L.1
Farnier, M.2
Macdonell, G.3
Perevozskaya, I.4
Davies, M.J.5
Gumbiner, B.6
Musliner, T.A.7
-
81
-
-
34249067115
-
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates
-
DOI 10.1185/030079907X187892
-
Rizzo M, Berneis K. The clinical significance of the size of lowdensity- lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin. 2007;23:1103-11. (Pubitemid 46799594)
-
(2007)
Current Medical Research and Opinion
, vol.23
, Issue.5
, pp. 1103-1111
-
-
Rizzo, M.1
Berneis, K.2
-
82
-
-
59649105853
-
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
-
Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res. 2008;49:2641-7.
-
(2008)
J Lipid Res.
, vol.49
, pp. 2641-2647
-
-
Farnier, M.1
Perevozskaya, I.2
Taggart, W.V.3
Kush, D.4
Mitchel, Y.B.5
-
83
-
-
34447314752
-
2 in obese patients with metabolic syndrome
-
DOI 10.1016/j.atherosclerosis.2006.07.010, PII S0021915006004084
-
Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007;193:428-37. (Pubitemid 47058108)
-
(2007)
Atherosclerosis
, vol.193
, Issue.2
, pp. 428-437
-
-
Filippatos, T.D.1
Gazi, I.F.2
Liberopoulos, E.N.3
Athyros, V.G.4
Elisaf, M.S.5
Tselepis, A.D.6
Kiortsis, D.N.7
-
85
-
-
0041641604
-
Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins
-
DOI 10.1194/jlr.M200452-JLR200
-
Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res. 2003;44:927-34. (Pubitemid 37279653)
-
(2003)
Journal of Lipid Research
, vol.44
, Issue.5
, pp. 927-934
-
-
Tsimihodimos, V.1
Kakafika, A.2
Tambaki, A.P.3
Bairaktari, E.4
Chapman, M.J.5
Elisaf, M.6
Tselepis, A.D.7
-
86
-
-
34248187694
-
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate
-
Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. Ann Clin Lab Sci. 2007;37:158-66. (Pubitemid 46717194)
-
(2007)
Annals of Clinical and Laboratory Science
, vol.37
, Issue.2
, pp. 158-166
-
-
Wu, T.-J.1
Ou, H.-Y.2
Chou, C.-W.3
Hsiao, S.-H.4
Lin, C.-Y.5
Kao, P.C.6
-
87
-
-
43149100565
-
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
-
DOI 10.1111/j.1463-1326.2007.00733.x
-
Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab. 2008;10:476-83. (Pubitemid 351639090)
-
(2008)
Diabetes, Obesity and Metabolism
, vol.10
, Issue.6
, pp. 476-483
-
-
Filippatos, T.D.1
Liberopoulos, E.N.2
Kostapanos, M.3
Gazi, I.F.4
Papavasiliou, E.C.5
Kiortsis, D.N.6
Tselepis, A.D.7
Elisaf, M.S.8
-
88
-
-
34548488210
-
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
-
DOI 10.1007/s00125-007-0751-8
-
Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia. 2007;50:2067-75. (Pubitemid 47373844)
-
(2007)
Diabetologia
, vol.50
, Issue.10
, pp. 2067-2075
-
-
Hiukka, A.1
Leinonen, E.2
Jauhiainen, M.3
Sundvall, J.4
Ehnholm, C.5
Keech, A.C.6
Taskinen, M.R.7
-
89
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
-
(2010)
N Engl J Med.
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
Crouse III, J.R.4
Leiter, L.A.5
Linz, P.6
-
90
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:1175-82.
-
(2009)
Lancet.
, vol.373
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
|